Old is gold? Retrospective evaluation of efficacy and safety of topical psoralen-UVA phototherapy for palmoplantar psoriasis and dermatitis.

Over the last decade new systemic drugs (e.g. biologics, apremilast, alitretinoin) have diversified the options for treating palmoplantar dermatoses such as psoriasis and dermatitis. Topical psoralen-UVA (tPUVA) phototherapy nevertheless remains an important modality for hand and foot dermatoses that may be refractory to topicals, with the advantage of avoiding systemic side effects or drug interactions. Protocols for tPUVA vary greatly in regard to psoralen concentration, vehicle, time interval between application and irradiation, as well as frequency. Uncontrolled studies have reported 58-87% clearance or significant improvement of psoriasis and 50-81% clearance or considerable improvement of eczema. Controlled studies have typically been underpowered and definitive evidence in support of this treatment modality is lacking. This article is protected by copyright. All rights reserved.